Erdheim-Chester Disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.


Disclosures: A.D has served as consultant for Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, and Novartis ; A.D has received research grants from National Cancer Institute, Roche ; O.A-W has served as a consultant for H3B Biomedicine, Foundation Medicine Inc, Merck, and Janssen; O.A.-W. has received prior research funding from H3B Biomedicine unrelated to the current manuscript. The other authors declare no competing financial interests for this work.

Contributions: J.R, J.F.E and J.H designed the study. The paper was written by J.R, E.D, F.C.A, J.F.E and J.H. All authors provided clinical, radiographic, histological and/or molecular data of the patients, participated in editing, and approved the final version of the manuscript.